Show simple item record

dc.contributor.authorGonzález Arceo, Maitane
dc.contributor.authorGómez López, Iván
dc.contributor.authorCarr Ugarte, Helen
dc.contributor.authorEseberri Barace, Itziar ORCID
dc.contributor.authorGonzález, Marcela
dc.contributor.authorCano, M. Pilar
dc.contributor.authorPortillo Baquedano, María Puy ORCID
dc.contributor.authorGómez Zorita, Saioa
dc.date.accessioned2023-01-13T17:36:13Z
dc.date.available2023-01-13T17:36:13Z
dc.date.issued2022-12-24
dc.identifier.citationInternational Journal of Molecular Sciences 24(1) : (2023) // Article ID 299es_ES
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/10810/59288
dc.description.abstractIsorhamnetin is a plant-derived secondary metabolite which belongs to the family of flavonoids. This review summarises the main outcomes described in the literature to date, regarding the effects of isorhamnetin on obesity from in vitro and in vivo studies. The studies carried out in pre-adipocytes show that isorhamnetin is able to reduce adipogenesis at 10 μM or higher doses and that these effects are mediated by Pparγ and by Wnt signalling pathway. Very few studies addressed in rodents are available so far. It seems that treatment periods longer than two weeks are needed by isorhamnetin and its glycosides to be effective as anti-obesity agents. Nevertheless, improvements in glycaemic control can be observed even in short treatments. Regarding the underlying mechanisms of action, although some contradictory results have been found, reductions in de novo lipogenesis and fatty acid uptake could be proposed. Further research is needed to increase the scientific evidence referring to this topic; studies in animal models are essential, as well as randomised clinical trials to determine whether the positive results observed in animals could also be found in humans, in order to determine if isorhamnetin and its glycosides can represent a real tool against obesity.es_ES
dc.description.sponsorshipThis study was supported by the Instituto de Salud Carlos III (CIBERobn) under Grant CB12/03/30007 and the Ministerio de Ciencia e Innovación (PID2020-118300RB-C21 and PID2020-118300RB-C22 co-funded by FEDER).es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/PID2020-118300RB-C21es_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/PID2020-118300RB-C22es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectisorhamnetines_ES
dc.subjectisorhamnetin glucosideses_ES
dc.subjectobesityes_ES
dc.subjectadipose tissuees_ES
dc.subjectadipocyteses_ES
dc.subjectanimal modelses_ES
dc.titleAnti-Obesity Effects of Isorhamnetin and Isorhamnetin Conjugateses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2023-01-06T13:52:41Z
dc.rights.holder© 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/1422-0067/24/1/299es_ES
dc.identifier.doi10.3390/ijms24010299
dc.departamentoesFarmacia y ciencias de los alimentos
dc.departamentoeuFarmazia eta elikagaien zientziak


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).
Except where otherwise noted, this item's license is described as © 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).